Elliot, E.C. : The effect of Persantin on coronary flow and cardiac dynamics. Canad. M. A. J., 85: 469, 1961.
2.
Grabner, G., Kaind, F., AND Kraupp, O.: The effect of 2,6-bis(diethanolamino)-4,8-dipiperidino-pyrimido [5,4-d] pyrimidine on cardiac activity and coronary circulation in anesthetized dogs. Arzneimittel-Forsch., 9: 45, 1959.
3.
Feruglio, F.S. , Migheli, B., Campus, S., Pandolfo, G., AND Accatino, G.: Studies on the circulation in the organs; effect of 2,6-bis[di-(α-hydroxyethyl)amino]-4,8-dipiperidine-pyrimido[5,4-d]pyrimidine on the coronary circulation of the dog. Minerva med., 51: 3793, 1960.
4.
Wendt, V.E., Sundermeyer, J.F., Den-Bakker, P.B. AND Bing, R.J.: The relationship between coronary blood flow, myocardial oxygen consumption and cardiac work as influenced by Persantin. Am. J. Cardiol. , 9: 449, 1962.
5.
West, J.W., Bellet, S., Manzoli, V.C., AND Mueller, O.F.: Effects of Persantin (RA 8), a new coronary vasodilator, on coronary blood flow and cardiac dynamics in the dog. Circulation Res., 10: 35, 1962.
6.
Betz, E., ET AL: Measurement of myocardial blood flow with the thermal conductivity probe with regard to the effect of Persantin. 27th Congress Circulation Bad Nauheim, p. 321, 1961.
7.
Dorner, J., AND Wick, E.: Comparative investigations into the efficacy of commonly used coronary vasodilator drugs in anesthetized and unanesthetized dogs. Arzneimittel-Forsch. , 10: 631, 1960.
8.
Kadatz, R.: The pharmacology of 2,6-Bis (diaethanolamino)-4, 8-dipiperidino-pyrimido(5,4-d)pyrimidine, a new compound with coronary-dilatory properties. Arzneimittel-Forsch. , 9: 39, 1959.
9.
Menge, H.G., AND Kadatz, R.: Correlations between chemical structure and vasodilator action in pyrimido (5,4-d) pyrimidine derivates. Arzneimittel-Forsch., 9: 476, 1959. 10. Bretschneider, H.J., Frank, A., Bernard, V., Kochsiek, K., AND Scheler, F.: Effect of a pyrimidopyrimidine derivate on oxygen supply to the myocardium. Arzneimittel-Forsch., 9: 49, 1959.
10.
Hockerts, T. , AND Bögelmann, G.: Studies of the action of 2,6-bis-(diethanolamino)-4,8-dipiperidino-pyrimido (5,4-d) pyrimidine on the heart and circulation. Arzneimittel-Forsch. , 9: 47, 1959.
11.
Betz, E., Braasch, D., AND Hensel, H.: The action of 2,6-bis-(diethanolamino)-4,8 dipiperidino-pyrimido(5,4-d) pyrimidine on the blood flow of the myocardium, brain, kidney, liver, skin and skeletal muscles. Arzneimittel-Forsch., 11: 333, 1961.
12.
Bernsmeier, A. , AND Rudolph, W.: Myocardial metabolism. 27th Congress, German Society for Circulation Research, Bad Nauheim, p. 74, 1961.
13.
Kinsella, D. , Troup, W., AND Mcgregor, M.: Studies with a new coronary vasodilator drug: Persantin. Am. Heart J., 63: 146, 1962. 15. Peel, A.A.F., Blum, K., Lancaster, W.M., Dall, J.L., AND Chalmers, G.L.: Observations on the coronary vasodilator effect of Persantin. Scot. M. J., 6: 403, 1961.
14.
Knipping, H.W. , Bolt, W., AND Mikuliez, K.: Clinical experiences and experimental studies on a new pyrimido-pyrimidine derivative. Arzneimittel-Forsch. , 10: 364, 1960.
15.
Thorn, W.: Metabolitkonzentrationen im Herzmuskel unter normalen, hypoxischen und anoxischen Bedingungen; Verhandlungen der Deutschen Gesellschaft für Kreislaufforschung . 27th Congress, German Society for Circulation Research, Bad Nauheim, p. 82, 1961.
16.
Siess, M.: Funktion und Energiestoffwechsel des erschöpften Herzmuskels unter der Wirkung von 2,6-Bis-(diaethanolamino)-4,8-dipiperidino-pyrimido (5,4-d) pyrimidin . Arzneimittel-Forsch., 12: 683, 1962.
17.
Lamprecht, W. : Stoffwechsel, Energetik und regulatorische Mechanismen der Herzmuskelzelle; Verhandlungen der Dutschen Gesellschaft für Kreislaufforschung. 27th Congress, German Society for Circulation Research, Bad Nauheim, p. 16, 1961.
18.
Siess, M.: Investigations to influence the energy metabolism in the exhausted auricular preparation. 27th Congress, German Society for Circulation Research, Bad Nauheim, p. 259, 1961.
19.
Laudahn, G. : The effect of Persantin upon heart muscle sarcomas . Experientia, 17: 415, 1961.
20.
Hasselbach, W.: Contractile structures of cardiac muscle and contraction cycle. 27th Congress, German Society for Circulation Research, Bad Nauheim, p. 115, 1961.
21.
Hochrein, H. , Schneider, K.W., AND Sell, R.: Uber die Wirkung von 2,6-Bis (diathanolamino)-4,8 dipiperidinopyrimido (5, 4-d) pyrimidin auf das sufflziente und insuffiziente Herz. Nauny-Schmiedebergs Arch. exper. Path. u. Pharmakol. , 243: 119, 1962.
22.
Wezler, K.: The action of 2,6-bis-(diethanol-amino)-4,8-dipiperidino-pyrimido (5,4-d) pyrimidine upon the dynamics of the isolated, spontaneously-beating, cold blooded heart. Arzneimittel-Forsch., 11: 943, 1961.
23.
Kiese, M., Lange, G., AND Resag, K.: The effect of 2,6-bis-(diethanolamino)-4,8-dipiperidino-pyrimido (5,4-d) pyrimidine on blood flow through the experimental myocardial infarct and normal heart muscle. Ztschr. ges. exper. Med., 132: 426, 1960 .
24.
Gebhardt, W. : The action of 2,6-bis-(diethanolamino)-4,8-dipiperidino- pyrimido (5,4-d) pyrimidine upon the dynamics of the isolated, spontaneously beating, warm-blooded heart. Arzneimittel-Forsch., 11: 957, 1961.
25.
Gebhardt, W. , Dressel, J., Steim, H., AND Reindell, H.: Circulatory effects of 2,6-bis-(diethanolamino)-4,8-dipiperidino-pyrimido (5,4-d) pyrimidine upon the circulation. Arzneimittel-Forsch. , 11: 962, 1961.
26.
Kadatz, R., AND Schröter, H.W.: Experimental studies on a new drug for heart therapy. Medecine etHygiene, 541: 233, 1962.
27.
Laurent, D. , Chevrier, J.L., AND Mouquin, M.: Experimental study of the effects of Persantin on coronary circulation and on myocardial metabolism underbasal conditions. Presse méd., 69: 2292, 1961.
28.
Pillat, B.: The influence of Persantin on the action potential of the papillary muscle in the cat. Nauny-Schmiedebergs Arch. exper. Path. u. Pharmakol. , 241: 467, 1961.
29.
Kunz, W., AND Siess, M.: Energy gain in cardiac muscle with a hydrogen transferring pyrimidine derivative . Nauny-Schmiedebergs Arch. exper. Path. u. Pharmakol., 241: 529, 1961.
30.
Kanther, R. : Die kardiogene Hyperpyruviamie als Ausdruck der Myokardstoffwechselstörung und ihre medikamentose Beeinflussung. München. med. Wchnschr., 104: 40, 1962.
31.
Albach, E.: The behavior of lactic acid (LA), pyruvic acid (PA), and transaminase (SGOT and SGPT) in cardiac patients treated with Persantin. Med. Welt, 2: 993, 1960.
32.
Greif, S.: Clinical and experimental studies to determine the effect of Persantin in coronary disease. Wien. med. Wchnschr., 110: 463, 1960 .
33.
Adlam, J.P.: Persantin. Brit. M. J., 5240: 1686, 1961.
34.
Leimgardt, H. : A contribution to the treatment of coronary insufhciency. Medizinische, 49: 2408, 1959 .
35.
Geschke, H.J. : Clinical experiences with Persantin in cardiac disease. Landarzt, 36: 876, 1960.
36.
Röseler, E.: Clinical experiences with Persantin in the treatment of coronary and myocardial insufficiency. Med. Welt, 2: 2562, 1960.
37.
Fischer, K.K. , AND Fiegel, C.: Increase in oxygen supply to the myocardium by use of the pyrimido-pyrimidine group. Deutsche. med. J. , 10: 484, 1959.
38.
Junemann, P. : Persantin, a new compound for the treatment of coronary insufficiency. München med. Wchnschr., 101: 340, 1959.
De Castro, B., AND Parchi, C.: Preliminary results of tests with a new coronary dilator derived from pyrimido-pyrimidine (RA 8). Gior. clin. med., 41: 769, 1960.
43.
Bambor, H.J. : A contribution to the treatment of coronary circulatory disturbances. Med. Klinik., 55: 1155, 1960 .
44.
Hamm, J., Renschler, H.E., AND Zack, W.J.: Clinical studies on the action of Persantin in angina pectoris. Medizinische, 3: 120, 1959.
45.
Lang, O.: Treatment of coronary insufficiency with 2,6-bis-(diethanolamino)-4,8-dipiperidino-pyrimido (5,4-d) pyrimidine. Wien. med. Wchnschr., 50: 1006, 1959 .
46.
Pabst, H.W. : The action of a new coronary dilator 2,6-bis-(diethanolamino)-4,8-dipiperidino-pyrimido (5,4-d) pyrimidine. Med. Klinik., 54: 257, 1959.
47.
Spitzbarth, H.: A study of the circulatory and clinical effects of 2,6-bis-(diethanol-amino)-4,8-dipiperidino-pyrimido (5,4-d) pyrimidine . Arzneimittel-Forsch., 9: 59, 1959.
48.
Cova, N., AND Bregani, P.: Some preliminary observations on the use of a new coronary dilator (RA 8) in the coronary insufficiency syndrome. Minerva cardioangiol. , 8: 431, 1960.